(219 days)
The Pulse Oximeter FS10A and FS20A are portable, non-invasive devices intended for spot check monitoring of arterial hemoglobin oxygen saturation (SpO2) and pulse rate of adult patients (weighing ≥ 30 kg) in hospitals.
The proposed devices of Pulse Oximeter FS10A, FS20A are fingertip devices, which can display SpO2 and pulse rate value. The proposed devices consist of detector and emitter LED, CPU, display unit and power unit. The pulse oximeter works by applying a sensor to a pulsating arteriolar vascular bed. The sensor contains a dual light source and photo detector. The wavelength of one light source is 660 nm, which is red light; the other is 906nm, which is infrared light. Skin, bone, tissue, and venous vessels normally absorb a constant amount of light overtime. The photodetector in finger sensor collects and converts the light into electronic signal which is proportional to the light intensity. The arteriolar bed normally pulsates and absorbs variable amounts of light during systole and diastole, as blood volume increases and decreases. The ratio of light absorbed at systole is translated into an oxygen saturation measurement. This measurement is referred to as SpO2. The power sources of the proposed devices are 2 AAA alkaline batteries. All of the proposed devices have low battery voltage indicator function and all of the proposed devices will automatically power off when there is no signal for longer than 8 seconds. The proposed devices are not for life-supporting or life-sustaining, not for implant. The devices or transducers are not sterile and the transducers are reusable and do not need sterilization. The devices are for prescription. The devices do not contain drug or biological products. The Pulse Oximeters FS10A,FS20A share the same measurement principle and oximeter sensor and oxygen saturation module and power supply. The indented target population and use environment of the Pulse Oximeters FS10A, FS20A are the same. The devices are software-driven and the software validation is provided in Section of Software.
The provided document is a 510(k) premarket notification for the Pulse Oximeter, Model FS10A and FS20A. It primarily focuses on demonstrating substantial equivalence to a predicate device rather than providing a detailed report of a device's specific acceptance criteria and a study proving it. Therefore, much of the requested information, particularly regarding detailed study methodologies, sample sizes for training/test sets, expert qualifications, and adjudication methods, is not explicitly available in this document.
However, based on the information provided, here's what can be extracted and inferred:
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria for SpO2 accuracy are implicitly defined by the stated accuracy specifications related to the predicate device and the clinical trial conclusion. The reported performance is also explicitly stated.
| Metric | Acceptance Criteria (from predicate/comparison) | Reported Device Performance (FS10A/FS20A) |
|---|---|---|
| SpO2 Accuracy (70-99%) | ±2% (for predicate MD300C1) | FS10A: 70-99%: ±2% |
| SpO2 Accuracy (70-100%) | ±2% (for predicate MD300C2) | FS20A: 70-100%: ±2% |
| SpO2 Accuracy (0-69%) | No definition | FS10A/FS20A: No definition |
| Pulse Rate (PR) Accuracy | ±2bpm (30-99bpm) and 2% (100-235bpm) (for predicate) | FS10A/FS20A: ±3bpm |
| SpO2 Resolution | 1% | FS10A/FS20A: 1% |
| PR Resolution | 1 bpm | FS10A/FS20A: 1 bpm |
| SpO2 Display Range | 0-99% (MD300C1), 0-100% (MD300C2) | FS10A: 0-99%, FS20A: 0-100% |
| PR Display Range | 0-254 bpm (predicate) | FS10A/FS20A: 0-250 bpm |
Study Proving Device Meets Acceptance Criteria:
A clinical trial was conducted for the FS20A model, following ISO80601-2-61:2011, Annex EE.2 Procedure for invasive laboratory testing. The conclusion states that "the accuracy Arms of the proposed device is smaller than 2%," which indicates it meets the standard for SpO2 accuracy within the specified range (70-100% for FS20A).
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size for Test Set: Not explicitly stated. The document only mentions "a clinical test for one of the proposed devices, and the model is FS20A." The specific number of subjects or data points is not provided.
- Data Provenance: The clinical test was conducted by the "Guangzhou Huangpu Traditional Chinese Medicine Hospital." This indicates the data is from China. It is implied to be prospective as it's a clinical trial related to the device's submission.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts
- This information is not provided in the document. The clinical trial described in the document is an "invasive laboratory testing" which likely involves direct measurement of arterial blood gas (ABG) for ground truth, rather than expert consensus on subjective data.
4. Adjudication Method for the Test Set
- This information is not provided in the document. Given the nature of a pulse oximeter clinical trial involving direct physiological measurements (ABG), "adjudication" in the sense of resolving conflicting expert opinions for ground truth is unlikely to be applicable. The ground truth would typically come from a reference standard instrument.
5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was done
- No, an MRMC comparative effectiveness study was not done. This document describes a clinical trial for a standalone device (pulse oximeter) to determine its accuracy against a reference standard, not a study evaluating human reader performance with or without AI assistance.
6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done
- Yes, a standalone study was done. The clinical trial described for the FS20A pulse oximeter is a standalone performance study. The device (algorithm and hardware) directly measures and displays SpO2 and pulse rate without human interpretation or intervention as part of the core measurement process.
7. The Type of Ground Truth Used
- The clinical trial followed "Annex EE.2 Procedure for invasive laboratory testing of ISO80601-2-61:2011," which for pulse oximeters, typically refers to invasive arterial blood gas (ABG) measurements as the reference standard for oxygen saturation. This is the gold standard for SpO2 ground truth.
8. The Sample Size for the Training Set
- This information is not provided in the document. The document describes a "clinical trial" which is usually a validation step for a device already developed, implying an algorithm may have been developed and "trained" prior to this validation. However, no details on a "training set" for the oximeter's algorithm are given.
9. How the Ground Truth for the Training Set Was Established
- This information is not provided in the document, as no details on a training set or its ground truth establishment are mentioned. If the device uses a machine learning algorithm, the ground truth for training would typically involve similar methods to the test set (e.g., ABG measurements).
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized representation of three human profiles facing right, stacked on top of each other. The profiles are black and have a flowing, wave-like appearance. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the profiles.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
December 4, 2014
Hunan Accurate Bio-Medical Technology Company Limited Mr. Li Zhang Quality Manager M8-613, No. 8, Lutian Road Changsha National Hi-Tech Industrial Development Zone Changsha, Hunan 410205 CHINA
Re: K141105 Trade/Device Name: Pulse Oximeter, Model FS10A and FS20A Regulation Number: 21 CFR 870.2700 Regulation Name: Oximeter Regulatory Class: II Product Code: DOA Dated: November 5, 2014 Received: November 5, 2014
Dear Mr. Zhang:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Page 2 - Mr. Zhang
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801): medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Tejashri Purohit-Sheth, M.D.
Tejashri Purohit-Sheth, M.D. Clinical Deputy Director DAGRID/ODE/CDRH FOR
Erin I. Keith, M.S. Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Druq Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: December 31, 2013 See PRA Statement on last page.
510(k) Number (if known)
Device Name
Pulse Oximeter
Indications for Use (Describe)
The Pulse Oximeter FS10A and FS20A are portable, non-invasive devices intended for spot check monitoring of arterial hemoglobin oxygen saturation (SpO2) and pulse rate of adult patients (weighing ≥ 30 kg) in hospitals.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
{3}------------------------------------------------
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{4}------------------------------------------------
Section 6 - 510(k) Summary
Date of Summary Preparation: 12/04/2014
1. Submitter's Identifications
Submitter's Name: Hunan Accurate Bio-Medical Technology Co., Ltd. Address: M8-613, No.8, Lutian Road, Changsha National Hi-Tech Industrial Development Zone, Changsha, Hunan Province, P.R. China Contact Person: Li Zhang Contact Email Address: Email: regulation@accbiomed.com Telephone: +86- 731-89745029 Fax: +86- 731-89745029
2. Correspondent's Identifications
Submitter's Name: Hunan Accurate Bio-Medical Technology Co., Ltd. Address: M8-613, No.8, Lutian Road, Changsha National Hi-Tech Industrial Development Zone, Changsha, Hunan Province, P.R. China Contact Person: Li Zhang Contact Email Address: regulation@accbiomed.com Telephone: +86- 731-89745029 Fax: +86- 731-89745029 3. Name of the Device Device Classification Name: Oximeter
Product Name: Pulse Oximeter Trade Name: Pulse Oximeter Model: FS10A,FS20A Classification Panel: Cardiovascular Product Code: DQA Device Classification: Class II
4. The Predicate Devices
K139047. MD300C1,MD300C2 Fingertip pulse Oximeter 21 CFR 870.2700
5. Device Description
The proposed devices of Pulse Oximeter FS10A, FS20A are fingertip devices, which can display SpO2 and pulse rate value. The proposed devices consist of detector and emitter LED, CPU, display unit and power unit.
The pulse oximeter works by applying a sensor to a pulsating arteriolar vascular bed. The sensor contains a
{5}------------------------------------------------
dual light source and photo detector. The wavelength of one light source is 660 nm, which is red light; the other is 906nm, which is infrared light.
Skin, bone, tissue, and venous vessels normally absorb a constant amount of light overtime. The photodetector in finger sensor collects and converts the light into electronic signal which is proportional to the light intensity. The arteriolar bed normally pulsates and absorbs variable amounts of light during systole and diastole, as blood volume increases and decreases. The ratio of light absorbed at systole is translated into an oxygen saturation measurement. This measurement is referred to as SpO2.
The power sources of the proposed devices are 2 AAA alkaline batteries. All of the proposed devices have low battery voltage indicator function and all of the proposed devices will automatically power off when there is no signal for longer than 8 seconds.
The proposed devices are not for life-supporting or life-sustaining, not for implant. The devices or transducers are not sterile and the transducers are reusable and do not need sterilization. The devices are for prescription. The devices do not contain drug or biological products.
The Pulse Oximeters FS10A,FS20A share the same measurement principle and oximeter sensor and oxygen saturation module and power supply. The indented target population and use environment of the Pulse Oximeters FS10A, FS20A are the same.
The devices are software-driven and the software validation is provided in Section of Software.
6. Intended Use of Device
The Pulse Oximeter FS10A and FS20A are portable, non-invasive devices intended for spot check monitoring of arterial hemoglobin oxygen saturation (SpO2) and pulse rate of adult patients (weighing ≥ 30 kg) in hospitals.
7. Summary of Substantial Equivalence
| FS10A | FS20A | ||
|---|---|---|---|
| Display Range | Spo2 | 0~99% | 0~100% |
| PR | 0~250 bpm | 0~250 bpm | |
| MeasurementRange | Spo2 | 70~99% | 70~100% |
| PR | 25~250 | 25~250 | |
| Accuracy | Spo2 | 70~99%: ±2%0%~69%: no definition | 70~100%: ±2%0%~69%: no definition |
| PR | ±3 bpm | ±3 bpm | |
| Resolution | Spo2 | 1% | 1% |
Table 1: The difference between FS10A and FS20A.
{6}------------------------------------------------
| PR | 1 bpm | 1 bpm | |
|---|---|---|---|
| Display Screen | LED | OLED | |
| Pulse Beep | N | Y | |
| Pulse beat sound | N | Y | |
| Pulse sound On/Off function | N | Y | |
| Pulse waveform display | N | Y | |
| Four direction display | N | Y | |
| The shape and size of shell | The proposed devices have the same appearances and sizes. |
Table 2 : The difference between FS10A,FS20A and Predicate
| Compariosn Elements | Proposed Device | Predicate Device | Comparison | |
|---|---|---|---|---|
| Device Name | Pulse oximeter | Fingertip pulse Oximeter (K130947) | Similar | |
| Model | FS10A, FS20A | MD300C1,MD300C2 | ------- | |
| Regulation No. | 21 CFR 870.2700 | 21 CFR 870.2700 | Same | |
| Classification | II | II | Same | |
| Classification Name | Oximeter | Oximeter | Same | |
| Product Code | DQA | DQA | Same | |
| Indications for Use | The Pulse Oximeter FS10A and FS20A are portable, non-invasive devices intended for spot check monitoring of arterial hemoglobin oxygen saturation (SpO2) and pulse rate of adult patients (weighing ≥ 30 kg) in hospitals. | The Fingertip Pulse Oximeter MD300C series, are portable, non-invasive devices intended for spot checking of arterial hemoglobin oxygen saturation(SPO2) and pulse rate of adult and pediatric patient at hospital(including clinical use in internist/surgery, Anesthesia, and intensive care units). | Similar | |
| Comparison Statement | The proposed devices have the same indications for use and classification. | |||
| Components | The applicant device consists of photo detector and emitter LED, CPU, data display unit and power unit. | detector and emitter LED, signal amplify unit, CPU, data display unit and power unit. | Similar | |
| Design Principle | Skin, bone, tissue, and venous vessels normally absorb a constant amount of light over time. The photo detector in finger sensor collects and converts the light into electronic signal which is proportional to the light intensity. The arteriolar bed | Skin, bone, tissue, and venous vessels normally absorb a constant amount of light over time. The photo detector in finger sensor collects and converts the light into electronic signal which is proportional to the | Similar | |
| normally pulsates and absorbsvariable amount of light duringsystole and diastole, as bloodvolume increases and decreases.The ratio of light absorbed atsystole and diastole is translatedinto an oxygen saturationmeasurement. This measurementis referred to as SPO2. | light intensity. The arteriolarbed normally pulsates andabsorbs variable amount oflight during systole anddiastole, as blood volumeincreases and decreases. Theratio of light absorbed atsystole and diastole istranslated into an oxygensaturation measurement. Thismeasurement is referred to asSPO2. | |||
| Measurement | Red | 660nm | 660nm | Same |
| Wavelength | Infrared | 906nm | 940nm | Thewavelength ofIR led isdifferent. |
| Comparision Statement | The proposed devices have the same design principle and similar components. | |||
| Display Type | LED: FS10AOLED:FS20A | LED:MD300C1OLED:MD300C2 | Same | |
| Working time | Work about 18 hours continuously. | Work for 30 hours continuously | Same | |
| Power Supply | 2 * AAA | 2 * AAA | Same | |
| Display Data | SPO2, PR | SPO2, PR | Same | |
| Spo2 Display Range | 0 | 0 | Same | |
| Spo2 Accuracy | FS10A: 70 | MD300C1: 70 | Same | |
| Spo2 resolution | 1% | 1% | Same | |
| PR display range | 0~250 bpm | 0~254 bpm | The PR rangeof thepredicatedevice isbigger. | |
| PR Accuracy | ±3bpm | ± 2bpm(30 | The PRaccuracy ofthe predicatedevice ishigher. | |
| PR resolution | 1 bpm | 1 bpm | Same | |
| Operating temperature | +5°~+40° C | +5°~+40°C | Same | |
| Relative humidity | 10%~95%(Operating and storage) | ≤80%(Operating)≤93%(storage) | Similar | |
| Atmosphere pressure | 70 | 86~106 kPa | Similar | |
| Pulse Beep | Available: FS20ANot Available: FS10A | Not Available | The predicatedevicedoesn't havethe Beepfunction. | |
| Comparison Statement | The applicant device has similar device specifications as the predicate device. | |||
| ContactingMaterial | Batterycover | ABS + PC | ABS | Similar |
| FingertipCushion | Medical Silicon gel | Medical Silicon gel | Same | |
| Enclosure | ABS + PC /PMMA | ABS | Similar | |
| Comparsion Statement | The contacting materials of applicant device are similar to that of the predicate device. | |||
| PerformanceTesting | Bench Test | The bench test include SpO2accuracy test , pulse rate test, FFCbending test, drop test, function testand test according toISO80601-2-61.All the bench testresults are provide in performanceTesting-Bench | Meet the requirements ofFDA Guidance. | Similar |
| Clinical Test | Conformed to ISO80601-2-61Clinical test for device accuracy isconducted by the GuangzhouHuangpu Traditional ChineseMedicine Hospital. The clinical testreport and protocol are provide inperformance Testing-clinical | Conformed to ISO 9919 | Similar | |
| ElectromagneticCompatibilitySafety | ElectricalSafety | Conformed to IEC60601-1.The test results are provided inElectromagnetic Compatibility andElectrical Safety. | Conformed to IEC60601-1 | Same |
| ElectromagneticCompatibility | Conformed to IEC60601-1-2.The test results are provided inElectromagnetic Compatibility andElectrical Safety. | Conformed to IEC60601-1-2 | Same | |
| Software | Moderate level of Concern | Moderate level ofConcern | Same | |
| Compliance with FDA Guidance forthe content of Premarket Submissionsfor Software Contained in MedicalDevices. | Compliance with FDAGuidance for the contentofPremarketSubmissions for SoftwareContained in MedicalDevices. | Same | ||
| Biocompatibility | MedicalSilicone gel | In Vitro No cytotoxicCytotoxicity potentialSkin Irritation Test No evidence ofcausingsensitizationSkin Sensitization No evidence ofTest significantirritation fromthe test extractto rabbits | In Vitro No cytotoxicCytotoxici potentialtySkin Irritation No evidenceTest of causingsensitizationSkin No evidenceSensitizati ofon Test significantirritationfrom thetest extractto rabbits | Same |
| ABS + PC/PMMAplastic | In Vitro No cytotoxicCytotoxicity potentialSkin Irritation Test No evidence ofcausingsensitizationSkin Sensitization No evidence ofTest significantirritation fromthe test extractto rabbits | In Vitro No cytotoxicCytotoxici potentialtySkin Irritation No evidenceTest of causingsensitizationSkin No evidenceSensitizati ofon Test significantirritationfrom thetest extractto rabbits | Same | |
| Label and Labeling | Compliance with FDA guidance |
{7}------------------------------------------------
{8}------------------------------------------------
{9}------------------------------------------------
8. Substantial Equivalence:
The proposed devices of Pulse Oximeter FS10A, FS20A have the same classification information, same indications and intended use, same design principle, similar product design and specifications, same performance effectiveness, performance safety as the predicate device.
The differences only exist in such contents: Infrared wave length, PR display range and accuracy and Pulse
Beep function. These differences are slight and do not influence the effectiveness and safety of the device.
{10}------------------------------------------------
According to the non-clinical and clinical test results, the proposed devices are as safe, as effective and perform as well as the predicate device. So the proposed devices are Substantially Equivalent(SE) to the predicate device which is US legally market device.
9. Non-Clinical Tests Performed:
The following testing was performed on the Pulse Oximeter FS10A,FS20A in accordance with the requirements of the design control regulations and established quality assurance procedures.
IEC60601-1:2005+CORR.1(2006)+CORR.2(2007),Medical electrical equipment-Part 1:General requirements for basic safety, and essential performance.
IEC60601-1-2:2007, Medical electrical equipment-Part 1-2: General requirements for basic safety and essential performance - Collateral standard: Electromagnetic compatibility-Requirements and tests.
ISO80601-2-61:2011, Medical electrical equipment-Part 2-6 1: Particular requirements for basic safety and essential performance of pulse oximeter equipment.
ISO10993-1: 2009, Biological evaluation of medical devices -Part 1:Evaluation and testing within a risk management process
ISO10993-5:2009, Biological evaluation of medical devices - PartS5: Tests for In Vitro cytotoxicity.
ISO10993-10:2010, Biological evaluation of medical devices-Part10: Tests for irritation and skin sensitization
In addition to the compliance of voluntary standards, the software verification has been carried out according to the FDA Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices.
10. Clinical Trial Conclusion
The Pulse Oximeters FS10A and FS20A share the same pulse oximeter sensor, algorithm and oxygen saturation module. So we considered a clinical test of one of the proposed devices could cover that of other devices. The clinical test of other proposed devices can be exempted. And we conducted clinical test for one of the proposed devices, and the model is FS20A.
The clinical trial was performed according to Annex EE.2 Procedure for invasive laboratory testing of ISO80601-2-61:2011, Medical electrical equipment-Part 2-6 1: Particular requirements for basic safety and essential performance of pulse oximeter equipment.
It can be determined from the result of the clinical study that the accuracy Arms of the proposed device is smaller than 2%.
11. Substantially Equivalent Conclusion
The proposed device Pulse Oximeter FS10A,FS20A are determined to be Substantially Equivalent (SE) to the predicate device, Fingertip Pulse Oximeter (K130947) MD300C1,MD300C2 in respect of safety and effectiveness.
--- End of this section ---
§ 870.2700 Oximeter.
(a)
Identification. An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.(b)
Classification. Class II (performance standards).